Navigation Links
Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
Date:5/5/2011

SEATTLE, May 5, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its phosphodiesterase 7 (PDE7) inhibitors demonstrated robust efficacy in animal models of nicotine addiction.  These data add to earlier studies showing strong effects in models of cocaine addiction as well as binge eating.  Omeros' PDE7 program was founded on the Company's discovery of a previously unknown link between PDE7 and any movement disorder, such as Parkinson's disease.  Omeros believes that it also is the first to link PDE7 to any addiction or compulsive behavior, and is now advancing PDE7 inhibitors for the treatment of these as well as movement disorders. Omeros is collaborating on this program with both the National Institute on Drug Abuse (NIDA) and The Michael J. Fox Foundation.

The studies, conducted by well-recognized addiction researcher R. Ciccocioppo, Ph.D., and his colleagues at the University of Camarino, demonstrated that PDE7 inhibitors reduced nicotine self-administration and inhibited relapse induced by cues and stress.  Smoking is the leading cause of preventable disease, disability and death in the United States, and it is estimated that 1.3 billion people worldwide, or approximately 20% of the world's population, are smokers. The smoking cessation market was estimated at $3.1 billion in 2007. Chantix® (varenicline) is the pharmaceutical market leader for the treatment of nicotine addiction.  However, Chantix® received a black box warning from the U.S. Food and Drug Administration highlighting the risk of serious mental health events including changes in behavior, depressed mood, hostility, and suicidal thoughts when taking the drug.  PDE7 inhibitors are thought to exert their effect through a different mechanism than Chantix® and, therefore, may not have these side effects.

PDE7 appears to modulate the
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 2015  The findings of a year-long investigation conducted ... the company,s handling of its Recovery IVC filter ... nd , part one of the series ... least 27 fatalities, have been associated with the Recovery ... by C.R. Bard in 2004 which linked the Recovery ...
(Date:9/3/2015)... , Sept. 3, 2015 Research and Markets ... "Investigation Report on China Olmesartan Market, 2010-2019" ... olmesartan medoxomil was successfully developed by Sankyo Pharmaceuticals Co., ... 2002, olmesartan medoxomil was approved by FDA to enter ... the best- selling drug in the world after it ...
(Date:9/3/2015)... , Sept. 3, 2015 Research and ... of the "Investigation Report on China Tamsulosin ... Compared with other a1- adrenergic receptor ... selectivity and lower risk of urinary tract infections ... since its debut in 1993 in ...
Breaking Medicine Technology:IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 2IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 3China Olmesartan Investigation Market Report 2010-2019 2China Tamsulosin Market Investigation Report 2015 2
... , MOUNTAIN VIEW, Calif. , Jan. ... of a Phase I clinical trial of CCX168, an ... is a highly potent and very selective compound that ... the body,s complement system and a potent driver of ...
... , EXTON, Pa. , Jan. 28 ... medical technology company that provides innovative solutions and technologies for a ... three and six months ended December 31, 2009 . All ... to those provided in the Company,s January 15, 2010 ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 2ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 3ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 4Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 2Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 3Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 4Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 5Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 6Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 7Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 8Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 9Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 10Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 11Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 12Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 13Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 14Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 15Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 16Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 17Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 18Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 19Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 20
(Date:9/3/2015)... VA (PRWEB) , ... September 03, 2015 , ... ... the Spouse/Caregiver Scholarship applications are open for spring 2016. Scholarships are awarded two ... members. Hope For The Warriors® is a national nonprofit dedicated to restoring a ...
(Date:9/3/2015)... ... September 03, 2015 , ... Advice columnist, professional ... her debut book, “Stop Wasting Your Time Blaming Others for Your Life.” , ... guide to overcoming life’s obstacles by taking full responsibility for one’s life shares ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... comprehensive eating disorder treatment for adults and adolescents struggling with anorexia, bulimia, ... has joined the medical treatment team. As a Staff Psychiatrist, Dr. Calinoiu ...
(Date:9/3/2015)... ... 2015 , ... As a result of the Patient Protection ... insurance plans, more employers are moving to a self-funded model for pharmacy plans, ... United Benefit Advisors (UBA) Health Plan Survey. , UBA’s survey, the nation’s largest ...
(Date:9/3/2015)... ... 03, 2015 , ... ProScrub is a set of automated tools that allow ... custom speed effects without the use of keyframes. Utilize ProScrub's powerful sliders to ... are perfect complements to energetic video productions. ProScrub is a Final Cut ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2
... , , SAN RAMON, Calif., ... who plays Dwight Schrute on NBC,s hit show The Office, ... night, August 15, at the home of Gouya and Payam Zamani, ... Mona Foundation, a non-profit organization that supports social and economic development ...
... juice to combat urinary tract infections is ,unsatisfactory and ... day..." Not all medical problems require a state-of-the-art solution, ... from the corner shop could treat a widespread and ... touted as a simple solution for urinary tract infections, ...
... , , , ... a leading national law firm in the fight against mesothelioma and ... foremost trial attorneys in the country, has joined the firm as ... of asbestos cancer cases since the late 1970s. He has successfully ...
... , , , ... sanofi-aventis U.S. announced today that the U.S. Food and Drug ... six months and older for the relief of symptoms of ... hives) and for children age two years and older for ...
... Avacor ( ) P r oducts LLC ... in the hair re-growth industry, has recently teamed up with two charitable organizations, ... ), and Team Continuum ( http://www.teamcontinuum.net ). ... fighting cancer as well as to help find new ways to fight this prolific ...
... , ST. LOUIS, Aug. 24 ... the herbicide Atrazine have attorney and clean water advocate Steve ... transparency and accountability for the herbicide,s manufacturers. , , ... in the New York Times and the Peoria Journal Star ...
Cached Medicine News:Health News:Rainn Wilson ('Dwight' on The Office) Joins Reply.com at Fundraiser for Mona Foundation 2Health News:Decorated Trial Attorney Conard Metcalf Joins Simmons Firm as 'Of Counsel' 2Health News:Decorated Trial Attorney Conard Metcalf Joins Simmons Firm as 'Of Counsel' 3Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 2Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 3Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 4Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 5Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 6Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 7Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 8Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 9Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 10Health News:Avacor(R), a Leader in Hair Regrowth, Announces Charities of Choice: Team Continuum and City of Hope 2Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 2Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 3
... The Stryker Threaded ... surgeon yet another choice ... tunnel. Dilators provide compaction ... The compaction of bone ...
... Stryker Conquest Suture Retrievers ... that pierce through soft ... through the tissue to ... Conquest Retrievers are front ...
... The Arthroscopy Scissor is ideal for excising ... tissue debris in the joint. The serrated edge ... as well as hold tissue within the jaws ... left and right jaw curvatures, are the perfect ...
... offers state-of-the-art quality in an instrument of ... durability. Low profile cutting tips allow access ... I instruments are available in just about ... required for large and small joint arthroscopic ...
Medicine Products: